VaxGen
| Company type | Subsidiary |
|---|---|
| Industry | Health care |
| Founded | 1995 |
| Defunct | 2016 |
| Fate | Operations shut down with parent company's bankruptcy |
| Headquarters | , United States |
| Parent | diaDexus, Inc. (from 2010) |
VaxGen was a biopharmaceutical company based in the San Francisco Bay Area.
Founded in 1995 and based in South San Francisco, California, the company was engaged in the development of vaccines that immunize against infectious disease, notably AIDS. On July 28, 2010, VaxGen Inc. was acquired by diaDexus, Inc. in a reverse merger transaction.;[1] diaDexus filed for bankruptcy in 2016.[2] VaxGen, Inc. does not have significant operations.
AIDSVAX
[edit]In the 1990s, VaxGen developed and began trials of an AIDS vaccine called AIDSVAX. The National Institute of Allergy and Infectious Diseases (NIAID) worked with Vaxgen when Vaxgen was developing its AIDS vaccine. Specifically, NIAID and Vaxgen worked together on research projects related to the body's immune response to the vaccine. As of 1998, according to NIAID, "The three-year study [of AIDSVAX] is the first large-scale trial of an HIV preventive vaccine, and will involve 5,000 volunteers at about 40 clinical sites in North America." Dr. Anthony Fauci said, "The effort to develop a safe and effective vaccine against HIV/AIDS is a global imperative and the highest priority of the NIH AIDS research program."[3]
However, in 2003, it was announced that the preliminary trials of the vaccine, conducted in Thailand and North America, had been unsuccessful.[4][5] The company's analysis of its results, which resulted in some potentially positive outcomes among patient subgroups, was criticized by statisticians as inappropriate.[6]
Anthrax vaccine
[edit]Vaxgen had focused its recent efforts on a new form of anthrax vaccine, for which it was awarded a $877 million contract to provide the vaccine under the Project Bioshield Act.[7]
In December 2006, the United States Department of Health and Human Services (HHS) unilaterally withdrew the $877 million contract, sending the stock tumbling as low as $1.20 per share.[citation needed]
References
[edit]- ^ "VaxGen to Acquire diaDexus in a Stock-for-Stock Merger Under Revised Terms". Diadexus.
- ^ Area's diaDexus Files Chapter 7 Bankruptcy, Plans to Liquidate Assets, CFO to Step Down Immediately, Mark Terry, BioSpace.com published 14 June 2016
- ^ "NIAID Collaborates with VaxGen on Vaccine Studies" (Press release). National Institute of Allergy and Infectious Diseases. 18 August 1998. Retrieved 5 August 2014.
- ^ "BBC News article on the failure of the AIDSVAX trial". November 12, 2003. Retrieved January 6, 2010.
- ^ "Community Medical Research Institute Begins Inoculations in AIDSVAX Trial".
- ^ Critics Bash HIV Vaccine Trial Analysis by Mike Mitka JAMA. 2003;289(12):1491. doi:10.1001/jama.289.12.1491
- ^ Williams, David (August 2, 2008). "Anthrax scientist Bruce Ivins stood to benefit from a panic". Los Angeles Times. Retrieved 2008-08-01.
Ivins is listed as a co-inventor on two patents for a genetically engineered anthrax vaccine, federal records show. Separately, Ivins also is listed as a co-inventor on an application to patent an additive for various biodefense vaccines.
External links
[edit]Historically was http://www.VaxGen.com. This URL is no longer for the Vaxgen, Inc. in this article.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |